EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer
Combining SBRT with EGFR-TKI therapy was associated with longer PFS and OS in patients with EGFR-mutant NSCLC, supporting its potential as an effective therapeutic strategy.
Authors
- Ze Yuan (ORCID: https://orcid.org/0009-0006-6691-0818)
- Dingyi Yang (ORCID: https://orcid.org/0000-0003-4141-4755)
- Dan Tao (ORCID: https://orcid.org/0000-0002-9437-3646)
- Yong Jiang (ORCID: https://orcid.org/0000-0001-6047-3342)
- Erha Munai
- Wei Zhou (ORCID: https://orcid.org/0000-0002-3139-989X)
- Yongzhong Wu
- Siwei Zeng
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/jtd-2025-635
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00